While CV1 alone did not markedly reduce tumor size compared to the PBS control, its addition significantly enhanced the anti-tumor effects and improved mouse survival of CDH17-CAR-NK92 cells compared with CDH17-CAR-NK92 or CV1 monotherapy (Fig. 6C and D). This evidence concerns the gene CDH17 and neoplasm.